Back grey arrow rt.gif
 
 
Roche at AASLD
 
 
  AASLD: Interferon-free Regimen Containing Setrobuvir in Combination with Ritonavir-boosted Danoprevir and Ribavirin with or without Mericitabine in HCV Genotype 1 Treatment-naive Patients: Interim Results from the ANNAPURNA Study - (11/14/13)
 
AASLD: Sustained Immune Control in HBeAg-Positive Chronic Hepatitis B Patients Who Switched From Long-Term Entecavir Therapy to Peginterferon Alfa-2a (40KD): 1-Year Follow-Up of the OSST Study - (11/25/13)
 
AASLD: Virologic Response to Boceprevir Plus Peginterferon Alfa-2a (40KD) and Ribavirin in Treatment-naive Patients with Chronic Hepatitis C and HCV Genotype 1 Infection: Interim Analysis of Data From the International TriCo Study - (11/20/13)
 
AASLD: Outcome of Treatment with Peginterferon alfa-2a (40KD) in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B (CHB) in the Real-World: Interim Analysis of Data from the Large European S-Collate Cohort - (11/20/13)
 
64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org